Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis

Cancer Cell

Volumn 7, Issue 1, 2005, Pages 39-49

  Fernandez Zapico, Martin E ^a   Gonzalez Paz, Natalia C ^b   Weiss, Ellen ^a,b   Savoy, Doris N ^b   Molina, Julian R ^b   Fonseca, Rafael ^b   Smyrk, Thomas C ^b   Chari, Suresh T ^a   Urrutia, Raul ^a   Billadeau, Daniel D ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRAS PROTEIN; ONCOPROTEIN; P21 ACTIVATED KINASE 1; RAC1 PROTEIN; RNA; UNCLASSIFIED DRUG; VAV1 PROTEIN;

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; ONCOGENE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA INTERFERENCE;

EID: 19944432938     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.11.024     Document Type: Article

References (43)

1. Abe K., Whitehead I.P., O'Bryan J.P., Der C.J. Involvement of NH(2)-terminal sequences in the negative regulation of Vav signaling and transforming activity. J. Biol. Chem. 274:1999;30410-30418
2. Abe K., Rossman K.L., Liu B., Ritola K.D., Chiang D., Campbell S.L., Burridge K., Der C.J. Vav2 is an activator of Cdc42, Rac1, and RhoA. J. Biol. Chem. 275:2000;10141-10149
3. Aghazadeh B., Lowry W.E., Huang X.-Y., Rosen M. Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell. 102:2000;625-633
4. Bardeesy N., DePinho R.A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer. 2:2002;897-909
5. Betz R., Sandhoff K., Fischer K.D., van Echten-Deckert G. Detection and identification of Vav1 protein in primary cultured murine cerebellar neurons and in neuroblastoma cells (SH-SY5Y and Neuro-2a). Neurosci. Lett. 339:2003;37-40
6. Billadeau D.D., Mackie S.M., Schoon R.A., Leibson P.J. The Rho family guanine nucleotide exchange factor Vav-2 regulates the development of cell-mediated cytotoxicity. J. Exp. Med. 192:2000;381-392. a
7. Billadeau D.D., Mackie S.M., Schoon R.A., Leibson P.J. Specific subdomains of Vav differentially affect T cell and NK cell activation. J. Immunol. 164:2000;3971-3981. b
8. Bottinger E.P., Jakubczak J.L., Roberts I.S., Mumy M., Hemmati P., Bagnall K., Merlino G., Wakefield L.M. Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas. EMBO J. 16:1997;2621-2633
9. Brummelkamp T., Bernards R., Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2:2002;243-247
10. Bustelo X.R. Regulatory and signaling properties of the Vav family. Mol. Cell. Biol. 20:2000;1461-1477
11. Bustelo X.R., Suen K.L., Leftheris K., Meyers C.A., Barbacid M. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor. Oncogene. 9:1994;2405-2413
12. Cao Y., Janssen E.M., Duncan A.W., Altman A., Billadeau D.D., Abraham R.T. Pleiotropic defects in TCR signaling in a Vav-1-null Jurkat T-cell line. EMBO J. 21:2002;4809-4819
13. Denkinger D.J., Borges C.R., Butler C.L., Cushman A.M., Kawahara R.S. Genomic organization and regulation of the vav proto-oncogene. Biochim. Biophys. Acta. 25:2000;1-3
14. Doody G.M., Bell S.E., Vigorito E., Clayton E., McAdam S., Tooze R., Fernandez C., Lee I.J., Turner M. Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation. Nat. Immunol. 2:2001;542-547
15. Fukata M., Kaibuchi K. Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat. Rev. Mol. Cell Biol. 2:2001;887-897
16. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., et al. Preinvasive and invasive ductular pancreatic cancer and its early detection in the mouse. Cancer Cell. 4:2003;437-450
17. Hornstein I., Pikarsky E., Groysman M., Amir G., Peylan-Ramu N., Katzav S. The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas. J. Pathol. 199:2003;526-533
18. Hruban R.H., Iacobuzio-Donahue C., Wilentz R.E., Goggins M., Kern S.E. Molecular pathology of pancreatic cancer. Cancer J. 7:2001;251-258
19. Itoh R.E., Kurokawa K., Ohba Y., Yoshizaki H., Mochizuki N., Matsuda M. Activation of Rac and Cdc42 video imaged by fluorescent resonance energy transfer-based single-molecule probes in the membrane of living cells. Mol. Cell. Biol. 22:2002;6582-6591
20. Jaffee E.M., Hruban R.H., Canto M., Kern S.E. Focus on pancreas cancer. Cancer Cell. 2:2002;25-28
21. Katzav S., Martin-Zanca D., Barbacid M. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J. 8:1989;2283-2290
22. Katzav S., Cleveland J.L., Heslop H.E., Pulido D. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol. Cell. Biol. 11:1991;1912-1920
23. Katzav S., Packham G., Sutherland M., Aroca P., Santos E., Cleveland J.L. Vav and Ras induce fibroblast transformation by overlapping signaling pathways which require c-Myc function. Oncogene. 11:1995;1079-1088
24. Khosravi-Far R., Chrzanowska-Wodnicka M., Solski P.A., Eva A., Burridge K., Der C.J. Dbl and Vav mediate transformation via mitogen-activated protein kinase pathways that are distinct from those activated by oncogenic Ras. Mol. Cell. Biol. 14:1994;6848-6857
25. Korc M. Role of growth factors in pancreatic cancer. Surg. Oncol. Clin. N. Am. 7:1998;25-41
26. Lopez-Lago M., Lee H., Cruz C., Movilla N., Bustelo X.R. Tyrosine phosphorylation mediates both activation and downmodulation of the biological activity of Vav. Mol. Cell. Biol. 20:2000;1678-1691
27. Matozaki T., Nakanishi H., Takai Y. Small G-protein networks. their crosstalk and signal cascades Cell. Signal. 12:2000;515-524
28. Movilla N., Bustelo X.R. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol. Cell. Biol. 19:1999;7870-7885
29. Movilla N., Dosil M., Zheng Y., Bustelo X.R. How Vav proteins discriminate the GTPases Rac1 and RhoA from Cdc42. Oncogene. 20:2001;8057-8065
30. Murga C., Zohar M., Teramoto H., Gutkind J.S. Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-κB. Oncogene. 21:2002;207-216
31. Noren N.K., Niessen C.M., Gumbiner B.M., Burridge K. Cadherin engagement regulates Rho family GTPases. J. Biol. Chem. 276:2001;33305-33308
32. Ornitz D.M., Hammer R.E., Messing A., Palmiter R.D., Brinster R.L. Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science. 238:1987;188-193
33. Poch B., Gansauge F., Schwarz A., Seufferlein T., Schnelldorfer T., Ramadani M., Beger H.G., Gansauge S. Epidermal growth factor induces cyclin D1 in human pancreatic carcinoma. evidence for a cyclin D1-dependent cell cycle progression Pancreas. 23:2001;280-287
34. Qiu R.G., Chen J., Kirn D., McCormick F., Symons M. An essential role for Rac in Ras transformation. Nature. 374:1995;457-459. a
35. Qiu R.G., Chen J., McCormick F., Symons M. A role for Rho in Ras transformation. Proc. Natl. Acad. Sci. USA. 92:1995;11781-11785. b
36. Sahai E., Marshall C.J. RHO-GTPases and cancer. Nat. Rev. Cancer. 2:2002;133-142
37. Schuebel K.E., Bustelo X.R., Nielsen D.A., Song B.J., Barbacid M., Goldman D., Lee I.J. Isolation and characterization of murine vav2, a member of the vav family of proto-oncogenes. Oncogene. 13:1996;363-371
38. Schuebel K.E., Movilla N., Rosa J.L., Bustelo X.R. Phosphorylation- dependent and constitutive activation of Rho proteins by wild-type and oncogenic Vav-2. EMBO J. 17:1998;6608-6621
39. Turner M., Billadeau D.D. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat. Rev. Immunol. 2:2002;476-486
40. Turner M., Mee P.J., Walters A.E., Quinn M.E., Mellor A.L., Zamoyska R., Tybulewicz V.L. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity. 7:1997;451-460
41. Urrutia R., DiMagno E.P. Cellular and Molecular Mechanisms Underlying the Development of Pancreatic Cancer, Volume II. 1997;Academic Press, New York
42. Wolff R.A. Novel therapies for pancreatic cancer. Cancer J. 7:2001;349-358
43. Zugaza J.L., Lopez-Lago M.A., Caloca M.J., Dosil M., Movilla N., Bustelo X.R. Structural determinants for the biological activity of Vav proteins. J. Biol. Chem. 277:2002;45377-45392